Table 5.

Results of the Sensitivity and Scenario Analyses

Sensitivity Analysis: 3-Year Cumulative Budget
Costs, $a	Current Market	New Market	Difference	Change, %
Base case	33,632,943	29,052,813	-4,580,130	-13.6
Patient weight increased 20% (86.4 kg)	40,161,965	33,069,366	-7,092,599	-17.7
Patient dose increased 20% (56.9 U/kg)	40,161,965	33,069,366	-7,092,599	-17.7
Adherence at 100% (ERT = 26 infusion per year; SRT = MPR 100%)	36,545,241	31,542,542	-5,002,699	-13.7
Scenario Analysis: 3-Year Cumulative Results
Scenario			Incremental Results, $ (%) (Reduction Compared to the Current Market)	PMPM, $
Scenario 1: Mature shift to eliglustat: 50%b			-5,162,841 (-15.4)	-0.029
Scenario 1: Mature shift to eliglustat: 100%b			-7,700,456 (-22.9)	-0.043
Scenario 2: Conservative markup: ERT cost markup is 20% at all sites of care.			-3,228,312 (-10.7)	-0.018
Scenario 3: Site of care management: The share of patients receiving ERT infusions in a hospital setting for the current and new market is reduced to 10% from 32% in the base case.			-2,490,957 (-8.9)	-0.014

^aAll costs are expressed in 2017 U.S. dollars.

^bPercentage of patients receiving ERT infusions in the hospital outpatient setting were shifted to eliglustat in the new market.

ERT = enzyme replacement therapy; MPR = medication possession ratio; PMPM = per member per month; SRT = substrate reduction therapy; U = unit.